Department of Pharmacy, Children's Hospitals and Clinics of Minnesota, Minneapolis, MN 55404, USA.
Pharmacotherapy. 2009 Nov;29(11):1297-305. doi: 10.1592/phco.29.11.1297.
To determine the pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol for critically ill neonates.
Retrospective medical record review with pharmacokinetic analysis.
Two neonatal intensive care units in a pediatric tertiary care system.
Sequential sample of 644 critically ill neonates less than 7 days old without evidence of renal dysfunction who received gentamicin, dosed by using a simplified, weight-based, extended-interval dosing protocol, on the first day of life for suspected sepsis between February 2003 and January 2008, and who had subsequent gentamicin plasma concentrations measured during their first week of life.
Data were collected on birth weight, gestational age at birth, serum creatinine concentration during the first 10 days of life, medical conditions, and concomitant drugs. Gentamicin dosing and its pharmacokinetic parameters were noted for each patient. A mean dose of 3.96 mg/kg/dose of gentamicin was administered intravenously every 48 hours in neonates weighing less than 1250 g at birth and every 24 hours in those weighing 1250 g or more. If the neonate received concurrent indomethacin, however, gentamicin was given every 48 hours. Protocol success was defined as a peak gentamicin plasma concentration of 7-10 mg/L and a trough concentration less than 2 mg/L. Mean gentamicin peak and trough concentrations were 9.38 mg/L (95% confidence interval [CI] 9.24-9.52 mg/L) and 1.00 mg/L (95% CI 0.96-1.04 mg/L), respectively. With use of the protocol, 361 neonates (56.1%) achieved gentamicin peak plasma concentrations in the range defined as successful and 610 neonates (94.7%) achieved successful trough concentrations. The mean gentamicin apparent volume of distribution and half-life were 0.48 L/kg (95% CI 0.47-0.49 L/kg) and 8.31 hours (95% CI 8.09-8.52 hrs), respectively.
This simplified, weight-based, extended-interval gentamicin dosing protocol for critically ill neonates was effective in achieving therapeutic peak plasma concentrations of gentamicin in most of the patients and, as a high proportion of patients had acceptable trough concentrations, may minimize the potential for toxicity.
确定简化的基于体重的延长间隔庆大霉素给药方案在危重新生儿中的药代动力学结果。
回顾性病历回顾与药代动力学分析。
儿科三级医疗系统中的两个新生儿重症监护病房。
2003 年 2 月至 2008 年 1 月期间,在生命的第一天,对 644 名不到 7 天大且无肾功能障碍证据的患有败血症的危重新生儿进行了一项序贯样本研究,这些婴儿接受了简化的基于体重的延长间隔给药方案的庆大霉素治疗,且在生命的第一周期间测量了后续的庆大霉素血浆浓度。
收集了出生体重、出生时的胎龄、生命的前 10 天的血清肌酐浓度、医疗状况和伴随药物的数据。为每位患者记录了庆大霉素的剂量及其药代动力学参数。出生体重小于 1250g 的新生儿每 48 小时静脉注射 3.96mg/kg/剂量的庆大霉素,出生体重为 1250g 或以上的新生儿每 24 小时注射一次。但是,如果新生儿同时接受吲哚美辛治疗,则每 48 小时给予庆大霉素。方案成功定义为庆大霉素血浆峰浓度为 7-10mg/L,谷浓度低于 2mg/L。庆大霉素平均峰浓度和谷浓度分别为 9.38mg/L(95%置信区间 [CI]9.24-9.52mg/L)和 1.00mg/L(95%CI0.96-1.04mg/L)。使用该方案,361 名(56.1%)新生儿的庆大霉素峰值血浆浓度达到成功范围,610 名(94.7%)新生儿的庆大霉素谷浓度达到成功范围。庆大霉素的平均表观分布容积和半衰期分别为 0.48L/kg(95%CI0.47-0.49L/kg)和 8.31 小时(95%CI8.09-8.52 小时)。
这种简化的基于体重的延长间隔庆大霉素给药方案对危重新生儿是有效的,可使大多数患者达到庆大霉素的治疗性峰值血浆浓度,并且由于很大比例的患者有可接受的谷浓度,因此可能最大限度地减少毒性的潜在风险。